BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target lifted by equities research analysts at Truist Financial from $102.00 to $107.00 in a research report issued on Wednesday,Benzinga reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $110.00 price target on shares of BridgeBio Pharma in a research note on Tuesday. Get BridgeBio Pharma alerts:Get Our Latest Research Report on BBIOBridgeBio Pharma Stock PerformanceBBIO traded up $0.46 during trading on Wednesday, reaching $84.16. Benzinga analyst updateBridgeBio Pharma Company Profile(Get Free Report)BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Read MoreReceive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.